Search Results

Sunitinib Malate 500 mg  | 98.09%

TargetMol

Sunitinib is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-kit.

More Information Supplier Page

Birabresib 100 mg  | 99.06%

TargetMol

Birabresib is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity.

More Information Supplier Page

Birabresib 10 mg  | 99.06%

TargetMol

Birabresib is a synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity.

More Information Supplier Page

Ziritaxestat 10 mg  | 99.67%

TargetMol

Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients.

More Information Supplier Page

Ziritaxestat 100 mg  | 99.67%

TargetMol

Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients.

More Information Supplier Page

Doramapimod 200 mg  | 99.65%

TargetMol

Doramapimod is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.

More Information Supplier Page